Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-oxo-4h-chromene-2-carboxylic Acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethyl)-phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide
2. Hm-30181
3. Hm30181
1. 849675-66-7
2. Hm-30181
3. Hm30181
4. Hm-30181-a
5. Pgp Inhibitor Hm30181ak
6. Encequidar [usan]
7. Hm30181ak
8. K4i4i996o4
9. 4-oxo-4h-chromene-2-carboxylic Acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethyl)-phenyl-2h-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide
10. Hm30181a
11. Hm-30181a
12. N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
13. Unii-k4i4i996o4
14. 4h-1-benzopyran-2-carboxamide, N-(2-(2-(4-(2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-
15. 4h-1-benzopyran-2-carboxamide, N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl]phenyl]-2h-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-
16. N-(2-(2-(4-(2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4h-1-benzopyran-2-carboxamide
17. N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl]phenyl]-2h-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-4h-1-benzopyran-2-carboxamide
18. V5q
19. Encequidar [inn]
20. Encequidar (usan/inn)
21. Hm-30181 Free Base
22. Encequidar (hm30181)
23. Encequidar [who-dd]
24. Chembl4594298
25. Schembl13822558
26. Ex-a3429a
27. Dtxsid501100387
28. Bcp25240
29. Zib67566
30. Bdbm50567579
31. Hm 30181a
32. Mfcd25976625
33. S3431
34. Who 10861
35. Zinc68014383
36. Cs-6194
37. Db14070
38. Sb18921
39. Ac-36564
40. As-35283
41. Hy-13646
42. P-glycoprotein Inhibitor Hm30181ak
43. D11782
44. A857803
45. Q27281950
46. 4-oxo-4h-chromen-2-carboxylic Acid [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethyl]-phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide
47. N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1h)-yl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4h-chromene-2-carboxamide
48. N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1h)-yl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4h-chromene-2-carboxamide
Molecular Weight | 688.7 g/mol |
---|---|
Molecular Formula | C38H36N6O7 |
XLogP3 | 5.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 11 |
Exact Mass | 688.26454751 g/mol |
Monoisotopic Mass | 688.26454751 g/mol |
Topological Polar Surface Area | 139 Ų |
Heavy Atom Count | 51 |
Formal Charge | 0 |
Complexity | 1220 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of breast cancer , Treatment of soft tissue sarcoma
ABOUT THIS PAGE
43
PharmaCompass offers a list of Encequidar API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Encequidar manufacturer or Encequidar supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Encequidar manufacturer or Encequidar supplier.
PharmaCompass also assists you with knowing the Encequidar API Price utilized in the formulation of products. Encequidar API Price is not always fixed or binding as the Encequidar Price is obtained through a variety of data sources. The Encequidar Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A D11782 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of D11782, including repackagers and relabelers. The FDA regulates D11782 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. D11782 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A D11782 supplier is an individual or a company that provides D11782 active pharmaceutical ingredient (API) or D11782 finished formulations upon request. The D11782 suppliers may include D11782 API manufacturers, exporters, distributors and traders.
click here to find a list of D11782 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing D11782 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for D11782 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture D11782 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain D11782 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a D11782 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of D11782 suppliers with NDC on PharmaCompass.
D11782 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of D11782 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right D11782 GMP manufacturer or D11782 GMP API supplier for your needs.
A D11782 CoA (Certificate of Analysis) is a formal document that attests to D11782's compliance with D11782 specifications and serves as a tool for batch-level quality control.
D11782 CoA mostly includes findings from lab analyses of a specific batch. For each D11782 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
D11782 may be tested according to a variety of international standards, such as European Pharmacopoeia (D11782 EP), D11782 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (D11782 USP).